Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Sintilimab Guided by MRD in Stage II-IIIB NSCLC
NCT07120698Phase 2Recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Nov 2025
- Primary completion
- Jun 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Started Nov 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07120698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07120698.